05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
Carolyn Cross |
156,314,029 |
£19,930,039 |
Nicolas Loebel |
3,538,991 |
£451,221 |
Junaid Bajwa |
1,193,697 |
£152,196 |
Jean Duvall |
1,163,529 |
£148,350 |
Jean Charest |
353,356 |
£45,053 |
Simon Sinclair |
256,327 |
£32,682 |
Carolyn Cross |
118,091,377 |
£15,056,651 |
M&G Plc |
40,588,235 |
£5,175,000 |
Robert Cross |
25,858,400 |
£3,296,946 |
Albemarle Life Sciences Fund |
15,105,882 |
£1,926,000 |
CRUX Asset Management |
9,298,090 |
£1,185,506 |
Chelverton Asset Management |
7,957,311 |
£1,014,557 |
13:06 |
78,835 @ 12.70p |
12:04 |
100,000 @ 13.00p |
12:01 |
35,000 @ 13.30p |
09:47 |
8 @ 12.50p |
Chair |
Jean Charest |
CEO |
Carolyn Cross |
Top of Page
You are here:
research